---
schema_version: "secwatch.filing_event.v1"
accession: "0001576280-22-000091"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2022-11-03T23:59:59+00:00"
generated_at: "2026-06-22T09:00:25.293884+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Guardant Health Q3 revenue $117.4M (+24% YoY); cuts full-year revenue guidance to $440-450M

## Summary
- Q3 clinical test volume 32,400 (+42% YoY); biopharma tests 6,750 (+40% YoY).
- GAAP net loss per share -$1.58; non-GAAP -$1.18; Adj. EBITDA loss -$112.8M.
- Full-year 2022 revenue guidance lowered to $440-450M from $460-470M, citing challenging backdrop.
- FDA approved Guardant360 CDx as companion diagnostic for ENHERTU in HER2-mutant NSCLC.
- ECLIPSE readout and Shield PMA submission expected in Q4 2022.

## SEC filing metadata
- accession: 0001576280-22-000091
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2022-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000157628022000091/0001576280-22-000091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000157628022000091/gh-20221103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001576280-22-000091
- JSON: https://secwatch.observer/filing/0001576280-22-000091.json
- Plain text: https://secwatch.observer/filing/0001576280-22-000091.txt

## Key facts
- Earnings Releases
  Guardant Health, Inc. reported the quarter ended September 30, 2022 results: revenue $117.4 million, net income $162.0 million, EPS $1.58. Guidance lowered.
  - Period: the quarter ended September 30, 2022
  - Revenue: $117.4 million
  - Net income: $162.0 million
  - EPS: $1.58
  - Guidance: lowered
  - Result: reported results
  source text: use of its proprietary tests, vast data sets and advanced analytics, today reported financial results for the quarter ended September 30, 2022. Recent Highlights • Revenue of $117.4 million for the third quarter of 2022, an increase of 24% over the corresponding period of 2021 • Reported 32,400 tests to clinical customers and 6,750 tests to biopharmaceutical
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000157628022000091/0001576280-22-000091-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.